Ranbaxy posts $586 million loss due to charges

23 February 2012

India’s largest drugmaker Ranbaxy Laboratories (RAB: BO), which is 64% owned by Japan’s Daiichi Sankyo (TYO: 4568), yesterday reported financial results for the fourth-quarter and full-year 2011, showing that consolidated sales for the quarter reached $736 million, up from $468 million in the like 2010 period Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) were 25% of sales at $188 million, compared with $53 million.

For the full year, consolidated sales were $2.11 billion, for the first time surpassing the $2 billion level and up 13% on 2010, the company noted. EBITDA was 18% of sales at $381 versus $402 million.

The results took account of significant exceptional charges below the EBITDA line in the quarter on account of (i) Provision: $500 million in connection with the investigation by the US Department of Justice (The Pharma Letter December 22, 2011) and (ii) Forex: long term outstanding forex call options sold by the company in earlier years and foreign currency loans marked to market as a matter of prudent accounting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK